However, despite CRSwNP being characterized as type 2 inflammation disease, it remains uncertain if type 2 biomarkers like blood eosinophil counts (BECs), eosinophilic cationic protein (ECP) or serum IgE can predict sensitivity to Dupilumab and allow conclusions to be drawn about treatment success [22]. This evidence concerns the gene RNASE3 and chronic rhinosinusitis with nasal polyps.